Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.

Autor: Lonardi S; Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Rasola C; Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Lobefaro R; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Rossini D; Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Formica V; Medical Oncology Unit, Policlinico Tor Vergata, Roma, Italy., Scartozzi M; Department of Medical Sciences and Public Health, Medical Oncology Unit, 'Azienda Ospedaliero Universitaria' of Cagliari, University of Cagliari, Cagliari, Italy., Frassineti GL; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST), Meldola, Italy., Boscolo G; Medical Specialties Department, Oncology and Oncological Haematology, ULSS 3 Serenissima, Mirano, Italy., Cinieri S; Department of Medical Oncology, Hospital 'Senatore Perrino', Brindisi, Italy., Di Donato S; Department of Medical Oncology, General Hospital, Prato, Italy., Pella N; Department of Oncology, ASUFC University Hospital, Udine, Italy., Bergamo F; Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Raimondi A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Arnoldi E; Department of Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy., Antonuzzo L; Clinical Oncology Unit, Careggi University Hospital, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy., Granetto C; Medical Oncology, ASL CN1, Cuneo, Italy., Zustovich F; Dipartimento di Oncologia Clinica, UOC Oncologia di Belluno, AULSS 1 Dolomiti, Ospedale S. Martino, Belluno, Italy., Ronzoni M; Oncologia Medica, IRCCS Ospedale San Raffaele, Milano, Italy., Leo S; Medical Oncology Unit, Vito Fazzi Hospital, Lecce, Italy., Morano F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Loupakis F; Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Buggin F; Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Zagonel V; Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Fassan M; Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University of Padova, Padova, Italy.; Veneto Institute of Oncology IOV-IRCCS, Padova, Italy., Cremolini C; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Boni L; IRCCS Ospedale Policlinico San Martino, Genova, Italy., Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 01; Vol. 41 (34), pp. 5263-5273. Date of Electronic Publication: 2023 Aug 03.

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

Autor: Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, Sara Lonardi, Fotios Loupakis, Filippo Pietrantonio, Roberto Bordonaro, Tiziana Pia Latiano, Emiliano Tamburini, Daniele Santini, Alessandro Passardi, Federica Marmorino, Roberta Grande, Giuseppe Aprile, Alberto Zaniboni, Sabina Murgioni, Cristina Granetto, Angela Buonadonna, Roberto Moretto, Salvatore Corallo, Stefano Cordio, Lorenzo Antonuzzo, Gianluca Tomasello, Gianluca Masi, Monica Ronzoni, Samantha Di Donato, Chiara Carlomagno, Matteo Clavarezza, Giuliana Ritorto, Andrea Mambrini, Mario Roselli, Samanta Cupini, Serafina Mammoliti, Elisabetta Fenocchio, Enrichetta Corgna, Vittorina Zagonel, Gabriella Fontanini, Clara Ugolini, Luca Boni, Alfredo Falcone, GONO Foundation Investigators

Publikováno v: SSRN Electronic Journal.

Background: The triplet FOLFOXIRI (fluorouracil, L-leucovorin, oxaliplatin, and irinotecan) plus bevacizumab showed improved outcomes of patients with metastatic colorectal cancer, when compared to FOLFIRI (fluorouracil, Lleucovorin, and irinotecan)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3bf7435cf1ff3aa5d9f46a1f65cea62b
https://doi.org/10.2139/ssrn.3478102

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.

Autor: Cremolini C; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy., Antoniotti C; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy., Rossini D; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy., Lonardi S; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy., Loupakis F; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy., Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; Oncology and Hemato-oncology Department, Università degli Studi di Milano, Milan, Italy., Bordonaro R; Medical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, Garibaldi Catania, Catania, Italy., Latiano TP; Oncology Unit, Foundation IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy., Tamburini E; Oncology Unit, Ospedale degli Infermi, Rimini, Italy; Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy., Santini D; Department of Medical Oncology, University Campus Biomedico, Rome, Italy., Passardi A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy., Marmorino F; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy., Grande R; Department of Medical Oncology, F Spaziani Hospital, Lazio, Italy., Aprile G; Department of Oncology, University and General Hospital, Udine, Italy; Department of Oncology, San Bortolo General Hospital, Vicenza, Italy., Zaniboni A; Medical Oncology Unit, Poliambulanza Foundation, Brescia, Italy., Murgioni S; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy., Granetto C; Department of Oncology, S Croce and Carle Teaching Hospital, Cuneo, Italy., Buonadonna A; Department of Medical Oncology, IRCCS, Centro di Riferimento Oncologico National Cancer Institute, Aviano, Italy., Moretto R; Department of Oncology, University Hospital of Pisa, Pisa, Italy., Corallo S; Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy., Cordio S; Medical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione, Garibaldi Catania, Catania, Italy., Antonuzzo L; Medical Oncology Unit, Careggi University Hospital, Florence, Italy., Tomasello G; Medical Oncology Unit, Azienda Socio-Sanitaria Territoriale of Cremona, Cremona Hospital, Cremona, Italy., Masi G; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy., Ronzoni M; Department of Oncology, Hospital San Raffaele, IRCCS, Milan, Italy., Di Donato S; Department of Medical Oncology, General Hospital, Prato, Italy., Carlomagno C; Department of Clinical Medicine and Surgery, University Federico II, Napoli, Italy., Clavarezza M; Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy., Ritorto G; Struttura Semplice Dipartimentale, ColoRectal Cancer Unit, Department of Oncology, Azienda Ospedaliero-Universitaria, Città della Salute e della Scienza di Torino, Turin, Italy., Mambrini A; Oncological Department, Azienda UnitàSanitaria Locale, Toscana Nord Ovest, Oncological Unit of Massa Carrara, Carrara, Italy., Roselli M; Department of Systems Medicine, Medical Oncology Unit, Tor Vergata University, Rome, Italy., Cupini S; Department of Oncology, Division of Medical Oncology, Azienda Toscana Nord Ovest, Livorno, Italy., Mammoliti S; Medical Oncology, IRCCS, Ospedale San Martino Istituto Scientifico Tumori, Genoa, Italy., Fenocchio E; Department of Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia, IRCCS, Candiolo, Italy., Corgna E; Unit of Medical Oncology, Ospedale Santa Maria della Misericordia, Perugia, Italy., Zagonel V; Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, IRCCS, Padua, Italy., Fontanini G; Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy., Ugolini C; Department of Laboratory, Pathology section, University Hospital of Pisa, Pisa, Italy., Boni L; Clinical Trials Coordinating Center, Toscano Cancer Institute, University Hospital Careggi, Florence, Italy., Falcone A; Department of Oncology, University Hospital of Pisa, Pisa, Italy; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy. Electronic address: alfredo.falcone@med.unipi.it.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2020 Apr; Vol. 21 (4), pp. 497-507. Date of Electronic Publication: 2020 Mar 09.

Spatial dynamics of CD39⁺CD8⁺ exhausted T cell reveal tertiary lymphoid structures-mediated response to PD-1 blockade in esophageal cancer.

Autor: Tanoue, Kenro, Ohmura, Hirofumi, Uehara, Koki, Ito, Mamoru, Yamaguchi, Kyoko, Tsuchihashi, Kenji, Shinohara, Yudai, Lu, Peng, Tamura, Shingo, Shimokawa, Hozumi, Isobe, Taichi, Ariyama, Hiroshi, Shibata, Yoshihiro, Tanaka, Risa, Kusaba, Hitoshi, Esaki, Taito, Mitsugi, Kenji, Kiyozawa, Daisuke, Iwasaki, Takeshi, Yamamoto, Hidetaka

Publikováno v: Nature Communications; 10/19/2024, Vol. 15 Issue 1, p1-18, 18p

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer.

Autor: Maiorano, Brigida Anna^1,2 (AUTHOR) b.maiorano@operapadrepio.it, Parisi, Alessandro^3,4 (AUTHOR), Maiello, Evaristo¹ (AUTHOR), Ciardiello, Davide^1,5 (AUTHOR)

Publikováno v: Life (2075-1729). Oct2022, Vol. 12 Issue 10, p1552-N.PAG. 16p.